Clinical Trials Logo

Clinical Trial Summary

Esketamine is an antagonist of N-methyl-d-aspartate (NMDA) receptor different from other gamma-aminobutyric acid (GABA) receptor agonists. Recent studies showed that subanesthetic doses of ketamine not only deepen anesthesia but also accelerate recovery from isoflurane anesthesia in mice. It is necessary to verify if it applies to human. Besides inducing behavioral unresponsiveness, an optimal and important goal of general anesthesia is to prevent connected consciousness. The results of many studies support the conclusion that anesthesia-related unconsciousness is a consistent functional disconnection of lateral frontoparietal networks.The goal of this clinical trial is to learn if subanaesthetic doses of esketamine works to accelerate the recovery of consciousness from propofol anesthesia. It will also learn about the change of brain network when administrated the esketamine during propofol anesthesia. The main questions it aims to answer are: 1. Does subanaesthetic doses of esketamine can accelerate recovery from propofol anaesthesia? 2. What will happen to brain network connection after different doses of esketamine during propofol anesthesia?


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06430645
Study type Interventional
Source Beijing Tiantan Hospital
Contact Yang Li, Master
Phone +86 18810637134
Email liyang0519@mail.ccmu.edu.cn
Status Recruiting
Phase N/A
Start date May 5, 2024
Completion date December 31, 2024

See also
  Status Clinical Trial Phase
Completed NCT03290495 - Ketamine Effect on Isoflurane Anesthesia Phase 4
Completed NCT01567852 - Use of Ketamine vs Methohexital for Electroconvulsive Therapy (ECT) on Patient Recovery and Re-orientation Time N/A